Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS12 | P56730 | 7/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 7/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.39 |
| ▸ | DHPS | P49366 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10184512 | 0.93 | UTS2R (0.47) | PRSS12UTS2RCHRNA7SLC6A2SLC6A4 | |
| SCHEMBL10186271 | 0.91 | UTS2R (0.42) | UTS2RCHRNA7SLC6A2SLC6A4 | |
| SCHEMBL10186255 | 0.89 | PRSS12 (0.41) | PRSS12UTS2RF10CHRNA7 | |
| SCHEMBL10185037 | 0.89 | NAMPT (0.46) | UTS2RSLC6A2SLC6A4 | |
| SCHEMBL10185104 | 0.87 | PRSS12 (0.44) | PRSS12UTS2RF10CHRNA7 | |
| SCHEMBL10186507 | 0.87 | PRSS12 (0.46) | PRSS12UTS2RF10CHRNA7 | |
| SCHEMBL10186508 | 0.86 | UTS2R (0.48) | UTS2RCHRNA7 | |
| SCHEMBL664007 | 0.84 | MAPK1 (0.41) | F10 | |
| SCHEMBL664008 | 0.84 | MAPK1 (0.41) | F10 | |
| SCHEMBL10186307 | 0.84 | MAPK1 (0.41) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | PRSS12 3098/4885UTS2R 2678/4885F10 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.